ABBV
APGE
Deal closed, now the real work starts
AbbVie says the acquisition of Apogee Therapeutics is done, which means the company just added a fresh batch of immunology assets to its already very busy medicine closet. The target basket includes zumilokibart, a late-stage monoclonal antibody aimed at IL-13 for atopic dermatitis, plus APG273, a longer-acting combo program for asthma.
Why investors should care
This is AbbVie doing what big pharma does when the patent clock starts tapping its watch: buying future growth instead of waiting for it to magically appear.
- Apogee gives AbbVie more shots on goal in dermatology and respiratory disease.
- The company is also keeping its 2026 adjusted EPS guidance intact at $13.87 to $14.07.
- Third-quarter adjusted EPS guidance also stays parked at $3.84 to $3.88.
The fine print that matters
That guidance reaffirmation is the real tell here. AbbVie isn’t signaling a sudden earnings boost from the deal today; it’s saying the purchase fits inside the current financial plan. In other words: strategic, not fireworks.
For shareholders, the question is whether these pipeline assets eventually turn into meaningful revenue or just another expensive “we’ll see” in a slide deck. Pharma M&A can be a little like buying a fancy espresso machine: impressive on day one, but the real test is whether it actually makes your mornings better.
Big picture: AbbVie is buying optionality, and in biotech land, optionality is often the whole game.